News

VitalStream Offers Continuous Hemodynamic Monitoring Solution Amid IV Fluid Shortage

Caretaker Medical, a pioneer in advanced hemodynamic monitoring technology, is highlighting the critical role of its VitalStream solution in addressing the ongoing IV fluid shortage caused by Hurricane Helene. As healthcare providers face challenges in maintaining continuous blood pressure monitoring due to the limited availability of Baxter IV fluids, VitalStream offers a reliable and innovative alternative.

VitalStream provides continuous hemodynamic monitoring without the need for invasive arterial lines or continuous IV fluid infusion. This groundbreaking technology eliminates the reliance on IV fluids for blood pressure measurement, offering significant advantages during times of supply shortages. By providing real-time insights into a patient’s response to fluids, VitalStream can potentially reduce the overall need for IV fluid administration.

“The IV fluid shortage has created a significant challenge for healthcare providers across the country,” said Johnny Mann, VP Sales and Marketing at Caretaker Medical. “VitalStream offers a valuable solution by enabling continuous hemodynamic monitoring without the need for invasive lines or constant IV fluid infusion. This technology can help ensure patient safety and optimize fluid management during these challenging times.”

Caretaker Medical will be showcasing VitalStream at the upcoming American Society of Anesthesiologists (ASA) Conference in Philadelphia from October 19-21. Attendees will have the opportunity to learn more about this innovative technology and its potential benefits in addressing the current IV fluid shortage.

Learn more here.

Recent News

05/14/2025

Civica to start Chesterfield lab construction this summer, eyes Petersburg plant expansion

Nearly three years after announcing plans to build a laboratory in Chesterfield to support its manufacturing operations in Petersburg, Civica Rx is readying plans to kick off the project’s construction. The Utah-based nonprofit drugmaker said it will break ground this summer on a 50,000-square-foot facility at 11731 Meadowville Lane, in the Meadowville Technology Park near Chester.

05/07/2025

Adial Pharmaceuticals raises $2.75M

Glen Allen biopharma company Adial Pharmaceuticals Inc. (NASDAQ: ADIL) has raised $2.75 million from an institutional investor. The company, which specializes in therapies for addiction and related disorders, said it will use the new funding for working capital and general corporate purposes. The name of the investor was not disclosed, but Adial said a “health

05/07/2025

Adovate Granted New U.S. Patent for Therapeutic Uses of A2B Receptor Antagonists

Adovate, LLC (“Adovate” or the “Company”), a biopharmaceutical company developing novel therapeutics targeting adenosine receptors involved in major diseases, today announced that Patent Number 12,269,828 B2 was issued by the United States Patent and Trademark Office. This newly issued patent covers therapeutic uses of the Company’s lead molecule ADO-5030 and thousands of other novel molecules